SCHEMBL30379751

SCHEMBL30379751

Clc1cccc2c1CCN=C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 3/20 0.36
HTR5A P47898 2/20 0.36
HTR1A P08908 1/20 0.36
HTR1D P28221 1/20 0.36
HTR2A P28223 1/20 0.36
HTR7 P34969 1/20 0.36
HTR3A P46098 1/20 0.36
ADRA2A P08913 1/20 0.35
CYP2D6 P10635 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
PNMT P11086 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
KDM1A O60341 1/20 0.32
CYP1A2 P05177 2/20 0.31
BCHE P06276 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9573136 1.00 HTR2C (0.36) HTR2CHTR5AHTR1AHTR1DHTR2A
SCHEMBL16246590 0.76 TRPA1 (0.44) HTR2C
SCHEMBL30024154 0.76 HTR5A (0.35) HTR2CHTR5AADRA2A
SCHEMBL30834466 0.76 TRPA1 (0.44) HTR2C
SCHEMBL16132820 0.76 CD44 (0.35) HTR2CTSHR
SCHEMBL9582682 0.76 HTR2C (0.36) HTR2CHTR5AADRA2AADRA2BADRA2C
SCHEMBL17103887 0.76 HTR5A (0.35) HTR2CHTR5AADRA2A
SCHEMBL30668656 0.76 CD44 (0.35) HTR2CTSHR
SCHEMBL13791331 0.75 HTR2C (0.33) HTR2C
SCHEMBL14861078 0.73 TRPA1 (0.47) HTR2CPNMTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540134-B2 Inhibitors of adrenoreceptor ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2026-02-03 US disclosed
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540134-B2 Inhibitors of adrenoreceptor ADRAC2 ADRA2C, ADRB3, ADRB2 HTR2C 58/4885HTR5A 221/4885HTR1A 174/4885
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 ADRA2C, ADRB2, ADRB3 HTR2C 61/4885HTR5A 440/4885HTR1A 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.